

General Announcement::Press Release - Trendlines Signs Definitive Collaboration Agreement with B. Braun Melsungen AG

Issuer & Securities

<b>Issuer/ Manager</b>	THE TRENDLINES GROUP LTD.
<b>Securities</b>	THE TRENDLINES GROUP LTD. - IL0011328858 - 42T
<b>Stapled Security</b>	No

Announcement Details

<b>Announcement Title</b>	General Announcement
<b>Date &amp; Time of Broadcast</b>	01-Mar-2016 07:01:58
<b>Status</b>	New
<b>Announcement Sub Title</b>	Press Release - Trendlines Signs Definitive Collaboration Agreement with B. Braun Melsungen AG
<b>Announcement Reference</b>	SG160301OTHRXKIC
<b>Submitted By (Co./ Ind. Name)</b>	Yosef Ron
<b>Designation</b>	Joint Company Secretary
<b>Description (Please provide a detailed description of the event in the box below)</b>	Please see attached.
<b>Attachments</b>	<a href="#">Trendlines B.Braun Collaboration Agreement Press Release 01 03 2016.pdf</a> Total size =209K



**For immediate release**

## **Trendlines Signs Definitive Collaboration Agreement with B. Braun Melsungen AG**

**Misgav, Israel – 1 March 2016** – The Trendlines Group Ltd. (the “**Company**” and together with its subsidiaries and associated companies, the “**Group**”) has signed a definitive collaboration agreement (“**Agreement**”) pursuant to the memorandum of understanding previously executed on 13 October 2015 with B. Braun Melsungen AG (“**B. Braun**”). Under the Agreement, the Company and B. Braun shall establish mutual deal flow, identify potential new investments, explore cooperation in the establishment of accelerators and incubators in selected markets worldwide, and collaborate on the development of new technologies, solutions and products in the medical field.

The Agreement is to leverage the Company's innovation and product development expertise and B. Braun's innovation activities and depth of market reach to develop, produce, and market breakthrough solutions for unmet market needs.

The agreed cooperation requires sharing information about market needs and developments, the potential establishment of jointly-owned accelerators and incubators, collaboration between the Company's Trendlines Labs in-house innovation center and B. Braun, and co-investment in selected portfolio companies of the Group.

Execution of the Agreement follows B. Braun's S\$7.1 million investment as a cornerstone investor in the Company's initial public offering on the Catalist of the Singapore Stock Exchange on 26 November 2015.

**Todd Dollinger, Chairman and CEO of The Trendlines Group comments:** "We are very pleased to have executed this partnership with market leader B. Braun, cementing the long relationship between our companies. This partnership allows us to expand our innovation capabilities and serves to help us fulfil our corporate mission of creating and developing companies to improve the human condition."

**Prof. Dr. Hanns-Peter Knaebel, member of the Executive Board of B. Braun Melsungen AG:** "The cooperation between Trendlines and B. Braun will give us a wide range of opportunities to invest in innovative early-stage med-tech companies to gain and maintain the quality leadership in our core product and service segments. With Trendlines as our partner in Israel we are able to profit from Israel's excellent innovation potential."

**-End-**

## About The Trendlines Group Ltd.

Trendlines established and invests in technology-based companies in the medical and agricultural fields, creating and developing companies in accordance with its mission to improve the human condition. To this end, Trendlines discovers, invests in, incubates, and supports life sciences medical and agricultural technologies companies.

---

For more information, please contact the IR representatives of The Trendlines Group in Singapore.

Romil SINGH / Reyna MEI

[romil@financialpr.com.sg](mailto:romil@financialpr.com.sg) / [reyna@financialpr.com.sg](mailto:reyna@financialpr.com.sg)

Tel: (65) 64382990, Fax: (65) 64380064

---

The Trendlines Group Ltd. (the "**Company**") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**").

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGXST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.